Kun-Bin Ke - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Current Medical Science|July 30, 2025

Physiological Reconstruction for Moderate-Severe Pelvic Organ Prolapse: A Multicenter Retrospective Self-Controlled StudyZhen-Hua Gao, Xing-Qi Wang, Kun-Bin Ke, et al.

Molecular Medicine (Cambridge, Mass.)|February 13, 2021

Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinomaYing Zhu, Kun-Bin Ke, Zhong-Kun Xia, et al.

Frontiers in Pharmacology|August 2, 2021

Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular CarcinomaZhong-Kun Xia, Wei Wang, Jian-Ge Qiu, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Current Medical Science|July 30, 2025

Physiological Reconstruction for Moderate-Severe Pelvic Organ Prolapse: A Multicenter Retrospective Self-Controlled StudyZhen-Hua Gao, Xing-Qi Wang, Kun-Bin Ke, et al.

Molecular Medicine (Cambridge, Mass.)|February 13, 2021

Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinomaYing Zhu, Kun-Bin Ke, Zhong-Kun Xia, et al.

Frontiers in Pharmacology|August 2, 2021

Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular CarcinomaZhong-Kun Xia, Wei Wang, Jian-Ge Qiu, et al.

Pageof 1